One year results from the REDUCE trial reported at TCT 2017

November 01, 2017

DENVER - November 1, 2017 - Results from the prospective, multicenter, randomized investigator-initiated REDUCE trial were reported today at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

The optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) treated with a drug-eluting stent is still under debate. The potential benefits of long-term DAPT in avoiding thrombotic complications may be offset by a higher risk of major bleeding complications. Researchers hypothesized that a reduction in DAPT duration could be achieved without increasing the overall treatment risk, by using the COMBO dual therapy stent, a stent designed to foster early re-endothelialization using a luminal anti-CD34 antibody with antiproliferative abluminal sirolimus elution.

From June 2014 to May 2016, 1,496 patients with acute coronary syndrome and treated with the COMBO dual therapy stent were randomly assigned to either three months (N=751) or 12 months (N=745) of DAPT. Clinical follow-ups were scheduled at three, six, 12, and 24 months. The primary study endpoint was a composite of all-cause mortality, myocardial infarction, stent thrombosis (ST), stroke, target-vessel revascularization (TVR), and bleeding (BARC II, III, V) at twelve months.

The trial found no difference in the primary endpoint between three and 12 months DAPT (8.2% vs. 8.4%, Pnoninferiority<0.001; Psuperiority=0.88). Among the secondary endpoints, major bleeding rates were similar among the treatment arms (2.5% vs. 3.0%, P=0.54), with non-significantly different rates of overall mortality (1.9% vs. 0.8%, P=0.07), cardiac mortality (1.1% vs. 0.4%, P=0.13), and definite/probable ST (1.2 % vs. 0.4%, P=0.08), although the study was not powered to assess these individual endpoints.

"The REDUCE trial shows that among ACS patients treated with a COMBO stent, three months of DAPT is non-inferior to 12 months of DAPT, and this is consistent for all pre-specified subgroups" said Harry Suryapranata, MD, PhD, Professor of Interventional Cardiology at Radboud University Medical Center in Nijmegen, The Netherlands. "Therefore, this strategy could be considered if needed, even in ACS population. Future larger trials are needed to further investigate and confirm the safety of short-term DAPT regimen in ACS patients in the era of new ADP antagonists and new generation DES."

The REDUCE trial is an investigator-initiated study funded by OrbusNeich. Dr. Suryapranata reported to have no conflicting personal financial interests, however his institution did receive an unrestricted research grant from OrbusNeich.
-end-
About CRF and TCT

The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and educate doctors on the latest treatments for heart disease.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. Now in its 29th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit http://www.crf.org and http://www.tctconference.com.

Cardiovascular Research Foundation

Related Acute Coronary Syndrome Articles from Brightsurf:

Effects of acute and chronic graft-versus-myelodysplastic syndrome on long-term outcomes following a
A research group led by Assistant Professor Takaaki Konuma in the Department of Hematology/Oncology, the Hospital of the Institute of Medical Science, the University of Tokyo (IMSUT Hospital) has demonstrated a graft-versus-tumor (GVT) effect of a previously unknown/novel allogeneic hematopoietic cell transplantation in MDS patients.

Effect of dexamethasone on days alive, ventilator-free in patients with COVID-19, acute respiratory distress syndrome
This randomized clinical trial in Brazil of 299 patients with COVID-19 and moderate or severe acute respiratory distress syndrome (ARDS) examined if intravenous dexamethasone plus standard care compared with standard care alone would increase the number of days patients were alive and free from mechanical ventilation.

UofSC researchers reveal how THC may treat acute respiratory distress syndrome
Acute Respiratory Distress Syndrome (ARDS), when caused by a bacterial toxin known as Staphylococcal enterotoxin, can be completely prevented by treatment with Δ9-tetrahydrocannabinol (THC), a cannabinoid found in the cannabis plant.

Fewer fungi types in lungs linked to worse disease in acute respiratory distress syndrome
Many COVID-19 patients develop acute respiratory distress syndrome (ARDS), a life-threatening condition where the lungs cannot provide the body's vital organs with enough oxygen.

Diagnosing acute aortic syndrome: New guideline for hard-to-diagnose condition
A new guideline aimed at helping clinicians identify the difficult-to-diagnose acute aortic syndrome is published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.200021.

Women taking beta blockers for hypertension may have higher risk of heart failure with acute coronary syndrome
Women have historically been underrepresented in past clinical research, raising concerns about their use of beta blockers as a treatment for hypertension.

Time to re-define sex-specific symptoms of acute coronary syndrome, say researchers
While there are differences between how women and men display in heart attack symptoms, researchers argue that continuing to simplify these symptoms as 'typical' or 'atypical' could contribute to delayed treatment and poorer health outcomes.

Does coronary microvascular spasm exist?
In a new publication from Cardiovascular Innovations and Applications; Fabian Guenther, Andreas Seitz, Valeria Martínez Pereyra, Raffi Bekeredjian, Udo Sechtem and Peter Ong from the Department of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany consider whether coronary microvascular spasm exists.

Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St.

Selective coronary angiography following cardiac arrest
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.

Read More: Acute Coronary Syndrome News and Acute Coronary Syndrome Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.